Humana’s (HUM) “Outperform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Humana (NYSE:HUM) in a report released on Wednesday,Benzinga reports. The brokerage currently has a $283.00 price target on the insurance provider’s stock.

HUM has been the subject of a number of other reports. Piper Sandler increased their price target on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Truist Financial increased their price target on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. TD Cowen raised their target price on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and lifted their price target for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Wednesday. Nineteen analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $293.05.

Humana Stock Performance

Humana stock opened at $253.61 on Wednesday. The business has a 50 day moving average of $271.83 and a 200-day moving average of $295.17. Humana has a 1 year low of $213.31 and a 1 year high of $406.46. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market capitalization of $30.54 billion, a P/E ratio of 22.46, a P/E/G ratio of 2.11 and a beta of 0.56.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, equities research analysts predict that Humana will post 16.11 earnings per share for the current year.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.32% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Humana

Institutional investors and hedge funds have recently modified their holdings of the stock. Solel Partners LP bought a new stake in shares of Humana during the 4th quarter worth approximately $1,116,000. Talon Private Wealth LLC bought a new position in shares of Humana in the 4th quarter worth $416,000. PDT Partners LLC grew its stake in Humana by 118.7% during the 4th quarter. PDT Partners LLC now owns 8,881 shares of the insurance provider’s stock worth $2,253,000 after buying an additional 4,821 shares during the last quarter. Leith Wheeler Investment Counsel Ltd. grew its stake in Humana by 1.9% during the 4th quarter. Leith Wheeler Investment Counsel Ltd. now owns 127,592 shares of the insurance provider’s stock worth $32,371,000 after buying an additional 2,390 shares during the last quarter. Finally, 8 Knots Management LLC purchased a new position in Humana during the 4th quarter worth $145,258,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.